EMERGENCY: Altered Level of Consciousness After Severe Vomiting

Step 1 - Immediate Actions (First 5 Minutes)

Step 2 - Differential Diagnosis

1. Severe Dehydration + Electrolyte Disturbance (Most Likely)

• Hyponatremia - loss of Na+ in vomitus + replacement with hypotonic fluids OR no intake. Acute hyponatremic encephalopathy causes cerebral edema and progresses to seizures, brainstem herniation, coma, and death. As Harrison's states: "Acute hyponatremic encephalopathy ensues when volume regulatory mechanisms are overwhelmed by a rapid decrease in tonicity, resulting in acute cerebral edema."
• Hypokalemia - severe K+ loss from vomiting
• Metabolic alkalosis - from H+ loss in gastric contents
• Hypoglycemia - no intake + repeated vomiting

2. Wernicke Encephalopathy (Thiamine Deficiency)

3. Medication Toxicity / Overdose

4. Aspiration + Hypoxia

5. Cerebral Event (must exclude)

6. Addisonian Crisis (Adrenal Insufficiency)

Step 3 - Immediate Investigations

Step 4 - Treatment

Empirical Treatment (Do Not Delay for Results)

• Acute hyponatremia (symptomatic, comatose): 3% hypertonic saline - target raise Na+ by 1-2 mEq/L/hour for the first few hours (to stop cerebral edema) - but do not correct >8-10 mEq/L in first 24 hours (risk of osmotic demyelination)
• As Tintinalli's states: "When the patient presents with severe neurologic symptoms (vomiting, seizures, reduced consciousness), the most important guide for therapy is symptoms rather than the serum Na+"

Step 5 - Warning Signs That Change Management

Summary

• This patient needs emergency care NOW - he cannot protect his airway
• The most likely cause is acute electrolyte disturbance (hyponatremia/hypokalemia) from prolonged vomiting
• Wernicke encephalopathy must be treated empirically - give thiamine BEFORE glucose
• Do NOT give hypotonic IV fluids
• Check blood glucose at bedside within the first minute
• Consider intubation if GCS does not improve rapidly

• Harrison's Principles of Internal Medicine 22E (2025) - Hyponatremia, p. 2757-2764
• Goldman-Cecil Medicine - Wernicke Encephalopathy, p. 3586-3652
• Tintinalli's Emergency Medicine - Treatment of Electrolyte Disorders

Paracetamol (Acetaminophen) Dose for a 17 kg Child

Dose Calculation

Volume to Give

Dosing Schedule

Practical Prescription

Paracetamol syrup 250 mg/5 mL Give 5 mL (250 mg) orally every 4-6 hours as needed for fever/pain. Do not exceed 5 doses in 24 hours.

• Do not give more frequently than every 4 hours
• Do not combine with other paracetamol-containing products (cold syrups, etc.)
• If fever persists >3 days or is >40°C, seek medical review

CT scan: Top-of-basilar syndrome showing bilateral medial thalamic infarcts and right occipital infarct - Neuroanatomy through Clinical Cases, 3rd Ed.

Bilateral Cerebral Hemisphere Infarcts + Severe Basilar Artery Narrowing - Causes

Understanding the Anatomy First

• Posterior cerebral arteries (PCAs) - supplying medial temporal and occipital lobes
• Thalamo-perforating arteries - bilateral thalamic supply
• Superior cerebellar arteries
• Pontine perforators

Causes - Classified by Mechanism

1. Intracranial Atherosclerosis (Most Common Overall)

• In-situ thrombosis on the plaque surface
• Artery-to-artery embolism - plaque ruptures and debris embolizes distally to bilateral PCAs
• Branch occlusion - plaque blocks origins of perforating arteries

2. Cardioembolism

3. "Top-of-Basilar" Syndrome

• Bilateral occipital lobe infarcts (cortical blindness)
• Bilateral thalamic infarcts (altered consciousness, memory loss)
• Midbrain infarcts (somnolence, diplopia, abnormal pupils)
• The basilar artery itself may appear narrowed from the embolus or underlying atherosclerosis

4. Vertebral Artery Dissection

5. Vasculitis - Inflammatory/Autoimmune

6. Hypercoagulable States

• Antiphospholipid syndrome - recurrent strokes in young patients; anti-cardiolipin antibodies
• Polycythemia vera - hyperviscosity
• Essential thrombocythemia
• Protein C / Protein S / Antithrombin III deficiency
• Factor V Leiden mutation
• Nephrotic syndrome (hypercoagulable from loss of anticoagulant proteins)
• Malignancy (Trousseau syndrome) - mucin-secreting adenocarcinomas

7. Basilar Artery Dolichoectasia

8. Hemodynamic (Watershed) Infarction

9. Genetic / Metabolic Causes (Rare)

• MELAS (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes) - stroke-like episodes NOT in vascular territory; bilateral; associated with seizures, lactic acidosis
• CADASIL (cerebral autosomal dominant arteriopathy) - young adults, leukoencephalopathy
• Fabry disease - alpha-galactosidase A deficiency; preferentially affects posterior circulation

Key Investigative Approach

Summary

Can Wernicke Encephalopathy or Severe Dehydration from Vomiting Cause Bilateral Cerebral Infarcts + Basilar Artery Narrowing?

1. Wernicke Encephalopathy (WE)

Can it directly cause cerebral infarcts? - NO (not true arterial infarcts)

Can it mimic infarcts on imaging? - YES, powerfully

Thiamine is an essential cofactor for energy metabolism. Its deficiency causes selective failure of oxidative metabolism in high-demand brain regions - not arterial occlusion.

The critical imaging trap:

• WE causes bilateral medial thalamic signal changes on MRI that look exactly like bilateral thalamic infarcts
• The DWI restriction (bright on diffusion-weighted imaging) mimics acute ischemic infarct
• This is the same pattern as "top-of-basilar" syndrome (bilateral thalamic + occipital infarcts from basilar apex occlusion)
• It is very easy to misdiagnose WE as bilateral PCA territory infarction

Does WE cause basilar artery narrowing? - NO

• A coincidence (the stenosis is the actual cause of thalamic infarcts)
• Artefact on MRA from slow/turbulent flow rather than true stenosis

WE can be caused by vomiting - YES

• Hyperemesis gravidarum
• Malignant GI obstruction
• Prolonged vomiting from any cause (including our motion sickness patient)

2. Severe Dehydration from Vomiting

Can it cause bilateral cerebral infarcts? - YES, via several mechanisms

A. Cerebral Venous Sinus Thrombosis (CVST) - Most important mechanism

"Most often, this (venous sinus thrombosis) occurs during a hypercoagulable state related either to dehydration, infection, or childbirth."

• Bilateral thalamic venous infarcts (can look like bilateral deep infarcts)
• Altered consciousness progressing to coma
• Nausea and vomiting (both a cause and symptom)

B. Hemodynamic/Watershed Infarction

C. Hyponatremia-induced Cerebral Edema (not infarction, but mimics it)

Can dehydration narrow the basilar artery? - INDIRECTLY

• Hemoconcentration + hypotension in the setting of pre-existing atherosclerotic plaque can trigger in-situ thrombosis on a narrowed basilar artery, making it appear severely stenosed on imaging
• MRA performed during dehydration/hypotension may show apparent "narrowing" due to slow or reduced flow rather than true stenosis (flow-related artifact)

3. The Combined Picture - Putting It Together

Severe Vomiting
     │
     ├── Thiamine depletion → WERNICKE ENCEPHALOPATHY
     │        └── Bilateral thalamic metabolic necrosis
     │            (mimics bilateral thalamic infarcts on MRI)
     │
     ├── Dehydration → CVST
     │        └── Bilateral thalamic venous infarcts
     │            (especially with deep venous thrombosis)
     │
     ├── Hypovolemia + pre-existing basilar stenosis
     │        └── Hemodynamic infarcts in posterior territory
     │
     └── Hyponatremia
              └── Cerebral edema → secondary ischemia

Clinical Bottom Line

Most important clinical action:

Seizure + Bloody Vomiting After Excessive Alcohol Consumption - Middle-Aged Man

1. Seizure - almost certainly alcohol withdrawal
2. Hematemesis (bloody vomiting) - most likely Mallory-Weiss tear, less likely variceal bleed

PART 1 - THE SEIZURE

Cause: Alcohol Withdrawal Syndrome (AWS)

Timeline of Alcohol Withdrawal

• Seizures occur in 5-10% of AWS patients
• Usually generalized tonic-clonic
• Two-thirds of patients who have one untreated seizure will have more
• 3% develop status epilepticus
• Most cluster at 6-48 hours after the last drink

Other Causes of Seizure to Consider in This Patient

PART 2 - BLOODY VOMITING (HEMATEMESIS)

Most Likely Cause: Mallory-Weiss Tear

"Longitudinal mucosal tears near the gastroesophageal junction, called Mallory-Weiss tears, are most most often associated with severe retching or vomiting secondary to acute alcohol intoxication."

Non-bloody vomiting/retching first → then hematemesis

• Accounts for 10-15% of upper GI bleeds
• Mortality ~5%
• Bleeding stops spontaneously in most cases
• Worsened significantly if patient has underlying cirrhosis/portal hypertension

Second Most Likely: Esophageal / Gastric Varices

• Accounts for the vast majority of GI bleeding in cirrhotics
• Massive, life-threatening hematemesis (often bright red, large volume)
• 50% of cirrhotics develop varices; 10-15% bleed per year
• Look for: spider angiomata, jaundice, ascites, caput medusae, palmar erythema, splenomegaly

Other Causes of Hematemesis

EMERGENCY MANAGEMENT

Immediate Priorities (Simultaneous)

AIRWAY first - this patient has seizures + vomiting = extreme aspiration risk
Intubation if GCS low, ongoing seizures, or massive hematemesis

Step-by-Step

Why Benzodiazepines for Seizure?

Investigations

Endoscopy (EGD)

• Mallory-Weiss tear: treat with epinephrine injection, clips, or band ligation
• Varices: band ligation is first-line endoscopic treatment
• If varices cannot be controlled: Sengstaken-Blakemore tube tamponade as bridge to TIPS (transjugular intrahepatic portosystemic shunt)

Summary Diagram

Middle-aged man + alcohol + vomiting + seizure + hematemesis
           │                          │
    ALCOHOL WITHDRAWAL          MALLORY-WEISS TEAR
    (12-48h after last drink)   (forceful retching → GEJ tear)
           │                          │
    Benzodiazepines               Endoscopy + PPI
    Thiamine first!              
    Check glucose                     
           │
    ± VARICEAL BLEED
    (if cirrhosis present)
    Octreotide + antibiotics + banding

1. Thiamine before glucose
2. Benzodiazepines - not phenytoin - for withdrawal seizures
3. Intubate early if airway compromised - vomiting + seizures = fatal aspiration
4. Alcohol withdrawal seizures often recur within hours - observe minimum 6 hours

Child with Suspected Glass Particle Ingestion

First - Reassure the Parents (Appropriately)

Step 1 - Immediate Assessment

Ask These Questions First

Red Flag Symptoms - Require Immediate Action

• Stridor, drooling, inability to swallow
• Neck or chest pain
• Vomiting blood (hematemesis)
• Abdominal pain or rigidity
• Respiratory distress
• Coughing/choking that won't settle

Step 2 - Why Glass Is a Special Case

• A normal X-ray does NOT rule out glass ingestion
• Standard coin/foreign body protocols do not fully apply
• If symptomatic, CT is needed

"CT scanning is a very high-yield test for esophageal foreign body and has generally replaced the barium swallow to evaluate ingestion of non-radiopaque objects."

"Radio-lucent + symptomatic witnessed ingestion: Urgent endoscopic evaluation and removal. Asymptomatic: Consider CT, ultrasound, MRI or esophagram for further assessment."

• Plain X-ray did NOT clearly identify the glass
• CT scan was required to locate it (found in gastric antrum)
• Conservative management was successful with vigilant monitoring

Step 3 - Management Algorithm

Child with suspected glass ingestion
              │
    ┌─────────┴──────────┐
 SYMPTOMATIC           ASYMPTOMATIC
    │                     │
Emergency assessment      │
Airway/ABC first          │
IV access                 │
Surgical consult          │
Urgent endoscopy          │
                  ┌───────┴────────┐
          Very small particles    Larger/sharp fragment
          (powder/dust-like)      (visible shard suspected)
                  │                       │
        Observe; educate parents    CT scan to locate
        Reassurance appropriate     + Surgical/GI consult
        Watch stools                + Likely endoscopy

If Asymptomatic with Tiny Glass Particles (Most Common Scenario)

• Often pass through GI tract without causing mucosal injury
• Drinking water naturally smooths micro-edges during transit
• Self-limited in most published cases

1. Thorough oral cavity examination - check mouth, gums, tongue for cuts
2. Neck and abdominal exam - tenderness, crepitus, distension
3. Plain X-ray (neck/chest/abdomen) - glass may not show but rules out other findings (free air = perforation)
4. If asymptomatic and tiny particles suspected - conservative observation is reasonable
5. Educate parents on warning signs to return

If a Larger Shard Is Suspected or Child is Symptomatic

"Ingestion of sharp or elongated objects" is a standalone indication for urgent endoscopy

Step 4 - What to Tell the Parents

Safe discharge with strict return precautions if:

• Child is completely asymptomatic
• No oral/pharyngeal cuts visible
• No abdominal tenderness
• Particles were described as tiny/powder-like
• X-ray shows no free air or obvious object

Return immediately if child develops:

• Drooling or difficulty swallowing
• Neck, chest, or abdominal pain
• Vomiting (especially with blood)
• Fever (suggests perforation/infection)
• Blood in stool (black/tarry stool = upper GI bleed)
• Refusal to eat or drink
• Breathing difficulty

Stool checking:

Step 5 - What NOT To Do

Summary Table

Clinical Analysis: 47-Year-Old Male, Exertional Breathlessness

CBC Parameters Interpretation

MCV (estimated) = PCV ÷ RBC count × 10. Without RBC count, we use clinical context.

Understanding RDW-SD

Diagnostic Possibilities Based on High RDW-SD

1. Iron Deficiency Anemia (IDA) - Most Likely

"Red cell distribution width (RDW) is often elevated, a measure of anisocytosis. Laboratory diagnosis may be demanding in patients with comorbidities. Classical microcytosis and hypochromia can be absent in elderly patients."

"Anemia develops only in the late stage of iron deficiency... anemia often remains undetected until hemoglobin falls below 8 g/dL."

2. Mixed Deficiency Anemia (Iron + B12/Folate)

3. Anemia of Chronic Disease / Inflammation

4. Thalassemia Trait + Iron Deficiency

5. Sideroblastic Anemia

6. Post-Transfusion / Recent Iron Treatment

Key Laboratory Pattern (From Tietz Laboratory Medicine)

Investigation Plan

Immediate (Confirm Diagnosis)

To Find the Cause (Critical in Middle-Aged Male)

"Tracing the cause may require imaging and endoscopy, procedures essential in males and postmenopausal females to rule out malignancy or other severe causes of bleeding."

Immediate Management

This Patient Needs Treatment Now (Hb 6 g/dL)

Clinical Summary

47-yr male + Hb 6 + PCV 23.9 + RDW-SD 48 fL + exertional dyspnea
              │
    Severe anemia with significant anisocytosis
              │
    Most likely: Iron Deficiency Anemia
    (from chronic GI blood loss until proven otherwise)
              │
    Also consider: Mixed IDA + B12/folate deficiency
                   Dimorphic / sideroblastic anemia
              │
    KEY INVESTIGATION: Ferritin, peripheral smear, B12, endoscopy
              │
    KEY CONCERN: Exclude GI malignancy (colon/gastric cancer)
              │
    TREATMENT: IV iron + transfusion if symptomatic + find and treat cause

Clinical Management: 37-Year-Old Obese Male with T2DM, Dyslipidemia, Grade 2 Fatty Liver - Shifting to Semaglutide

Why Semaglutide Is the Ideal Choice Here

The Evidence Base

For NAFLD/MASH (Strongest Recent Evidence)

In 1197 patients with biopsy-proven MASH + fibrosis stage 2-3, semaglutide 2.4 mg/week:

• Resolution of steatohepatitis: 62.9% vs 34.3% placebo (p<0.001)
• Reduction in fibrosis: 36.8% vs 22.4% placebo (p<0.001)
• Mean body weight loss: -10.5% vs -2.0% placebo

Across 8 studies (n=2413), semaglutide significantly reduced:

• ALT by 14 U/L, AST by 6.9 U/L
• Liver fat content by 4.97%
• Liver stiffness by 0.96 kPa
• Improved HbA1c and lipid profile

For Obesity + T2DM

The Medication Transition Plan

What to Stop and Why

Semaglutide Dosing - Two Options Based on Goal

Injection Technique

• Subcutaneous injection into abdomen, thigh, or upper arm
• Same day each week, any time of day, with or without food
• Rotate injection sites

Practical Transition Protocol

Week 1-4

• Stop glimepiride on Day 1 of semaglutide initiation (or taper over 1 week if high HbA1c and concerned about glucose control)
• Start semaglutide 0.25 mg SC once weekly
• Continue metformin at current dose
• Monitor blood glucose more frequently for first 2 weeks

Week 5-8

• Increase semaglutide to 0.5 mg/week
• Monitor HbA1c at 8 weeks

Week 9-12 onward

• Increase to 1 mg → 1.7 mg → 2.4 mg (4 weeks at each step)
• Slow titration reduces GI side effects

Monitoring Schedule

Managing the Fatty Liver (Grade 2 NAFLD)

1. Semaglutide - now the most evidence-backed pharmacotherapy for NAFLD/MASH
2. Weight loss 5-10% alone can reduce liver fat by 40-80% - semaglutide helps achieve this
3. Stop alcohol completely if any intake
4. Statin use is safe and beneficial in NAFLD + dyslipidemia - do NOT avoid statins for fear of liver toxicity (LFTs rarely worsen with statins in NAFLD)
5. Monitor: Repeat ultrasound and LFTs at 6 months to document regression
6. Consider FibroScan (transient elastography) to baseline liver stiffness and monitor for fibrosis

Managing Dyslipidemia

• High triglycerides
• Low HDL
• High small-dense LDL

• Atorvastatin 10-20 mg or Rosuvastatin 10 mg
• T2DM is a high CV risk state - statin is indicated
• Semaglutide itself reduces triglycerides and LDL, complementing statin therapy

Side Effects to Counsel the Patient On

Absolute Contraindications

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

Lifestyle - The Non-Negotiable Foundation

"With at least 5% and more so with 10% weight reduction, improvement in insulin sensitivity results in favorable modifications in many components of metabolic syndrome."

Summary Management Plan

37M - Obese + T2DM + Dyslipidemia + Grade 2 NAFLD
Currently: Metformin + Glimepiride

CHANGES:
✓ STOP Glimepiride (weight gain, hypoglycemia, no CV benefit)
✓ CONTINUE Metformin
✓ START Semaglutide 0.25mg SC weekly → titrate to 2.4mg
✓ ADD Statin (atorvastatin/rosuvastatin) for dyslipidemia
✓ Lifestyle: 500 kcal deficit + 150 min exercise/week
✓ Monitor: HbA1c, LFTs, lipids, weight, liver ultrasound at 6 months

EXPECTED OUTCOMES at 6-12 months:
- Weight: -10-15% body weight
- HbA1c: -1.4-1.6%
- Liver fat: significant regression of Grade 2 NAFLD
- Lipids: improved TG, LDL, HDL
- Cardiovascular risk: reduced

Oral Semaglutide - Complete Clinical Guide

The Pharmaceutical Innovation: How It Works

• SNAC is a fatty acid derivative that acts as an absorption enhancer
• It creates a microenvironment of locally high pH around the tablet in the stomach, protecting semaglutide from acid degradation
• SNAC also facilitates transcellular absorption through the gastric mucosa
• Result: semaglutide is absorbed directly through the stomach wall (not the intestine)

Currently Available Oral Semaglutide Formulations

1. Rybelsus (Oral Semaglutide for T2DM) - FDA approved 2019

• Take on an empty stomach first thing in the morning
• Swallow whole with max 120 mL (half glass) plain water ONLY
• Wait at least 30 minutes before eating, drinking anything other than water, or taking other medications
• Do NOT crush or split tablet

2. Oral Wegovy (High-Dose Oral Semaglutide for Obesity) - FDA approved December 2025

Head-to-Head: Oral vs Injectable Semaglutide

The PIONEER and OASIS Trial Evidence

PIONEER PLUS Trial (Lancet 2023 - PMID 37385279)

OASIS 1 Trial (Lancet 2023 - PMID 37385278)

• Mean weight loss: -15.1% at 68 weeks vs -2.4% placebo
• 85% of participants lost ≥5% body weight
• 54% lost ≥15% body weight
• This matches injectable Wegovy 2.4 mg performance

The conclusion: At 50 mg oral dose, weight loss equals the injectable 2.4 mg subcutaneous formulation.

Meta-analysis (Zhang et al., J Clin Pharmacol 2024 - PMID 38874130)

• HbA1c reduction: dose-dependent (3 mg: -0.61%, 7 mg: -1.12%, 14 mg: -1.08% vs placebo)
• Oral semaglutide outperformed sitagliptin, empagliflozin, liraglutide, and dulaglutide head-to-head
• Less hypoglycemia vs positive comparators (no sulfonylurea-level risk)
• GI side effects higher than placebo but manageable

For This Patient (37M, Obese + T2DM + Fatty Liver)

Should he use oral or injectable semaglutide?

• Injectable semaglutide 2.4 mg (Wegovy) is preferred - it has direct Phase 3 MASH/NAFLD evidence (NEJM 2025), better real-world compliance, and the highest weight loss data
• Oral semaglutide (Rybelsus 14 mg) is an acceptable alternative if patient refuses injections or has needle phobia - continue with metformin; titrate to 14 mg maximum
• Oral semaglutide 50 mg (if available) achieves comparable weight loss to injectable Wegovy and could be considered for obesity indication

Oral Semaglutide Dosing for T2DM (Rybelsus)

Month 1:  3 mg once daily (tolerability - minimal glucose effect)
Month 2:  7 mg once daily (therapeutic)
Month 3+: 14 mg once daily (maximum approved dose for T2DM)

Taking rules:
- Empty stomach on waking
- ≤120 mL water only
- Wait 30 min before anything else
- If missed: skip and resume next day (do NOT double dose)

Key Side Effects of Oral Semaglutide

Summary: Oral vs Injectable for This Patient

ORAL SEMAGLUTIDE (Rybelsus)
├── Available NOW for T2DM
├── 14 mg maximum dose
├── -1.1% HbA1c, ~4 kg weight loss
├── Good for: needle-averse patients
└── Limitation: less weight loss at approved T2DM dose; strict fasting rules

ORAL SEMAGLUTIDE 50 mg (new formulation)
├── Matches injectable Wegovy weight loss (-15%)
├── For obesity indication
└── Still rolling out globally (FDA approved Dec 2025)

INJECTABLE SEMAGLUTIDE 2.4 mg (Wegovy) ← PREFERRED FOR THIS PATIENT
├── Best NAFLD/MASH evidence (NEJM Phase 3 2025)
├── -15% weight loss, -10.5% in MASH trial
├── Once weekly - best adherence
└── Gold standard for obesity + T2DM + NAFLD